Drug Profile


Alternative Names: Anti-CD51 antigen mAb; Anti-integrin alphaV mAb; DI 17E6; EMD525797

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Serono; Merck Serono
  • Developer Merck Serono
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Integrin alphaV antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic scleroderma
  • Discontinued Colorectal cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 15 Apr 2016 Merck and EMD Serono Research & Development Institute plan a phase II trial for Systemic scleroderma (associated interstitial lung disease) in USA, Germany, France, Italy, Poland, Spain, United Kingdom, Argentina, Australia, Canada, Israel and Turkey (IV) (NCT02745145)
  • 01 Apr 2016 Phase-II clinical trials in Systemic scleroderma (associated interstitial lung disease) in USA, Spain (IV) (NCT02745145)
  • 18 Sep 2015 Efficacy data from the POSEIDON phase I/II trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) released by Merck (Merck's half year financial report,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top